论文部分内容阅读
目的:探讨添加恩他卡朋治疗帕金森病患者剂末现象的疗效及安全性。方法:17例伴有剂末现象的帕金森病患者进行添加服用恩他卡朋前后对照。根据患者日记记录的“开”“关”时间、UPDRSⅡ/Ⅲ评分、左旋多巴每天剂量来综合评估。结果:12周观察显示恩他卡朋添加治疗帕金森病剂末现象能够显著延长“开”时间、缩短“关”时间、降低UPDRSⅡ/Ⅲ评分,没有发现严重不良事件及实验室的异常改变。结论:帕金森病伴有剂末现象患者添加恩他卡朋治疗有效、安全。
Objective: To investigate the curative effect and safety of adding entacapone in treating patients with Parkinson’s disease. Methods: Seventeen patients with Parkinson’s disease with dosing agents were enrolled before and after adding entacapone. According to the patient’s diary records of “on” “off” time, UPDRS Ⅱ / Ⅲ score, levodopa daily dose to comprehensive assessment. Results: Twelve-week observation showed that the addition of natalocaline to Parkinson’s disease could significantly prolong the “on” time, shorten the “off” time and decrease the UPDRSⅡ / Ⅲ score. No serious adverse events or laboratory abnormalities were found. Conclusion: It is effective and safe to add entacapone in the patients with Parkinson’s disease accompanied by the end-dose.